Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700996 | 1.00 | PIK3C3 (0.63) | PIK3C3 | |
| SCHEMBL29700998 | 1.00 | PIK3C3 (0.63) | PIK3C3 | |
| SCHEMBL29701008 | 1.00 | PIK3C3 (0.63) | PIK3C3 | |
| SCHEMBL29701003 | 0.85 | PIK3C3 (0.77) | PIK3C3 | |
| SCHEMBL20765374 | 0.85 | PIK3C3 (0.77) | PIK3C3 | |
| SCHEMBL29035853 | 0.84 | PIK3C3 (0.63) | PIK3C3 | |
| SCHEMBL22655427 | 0.82 | PIK3C3 (0.60) | PIK3C3 | |
| SCHEMBL29700993 | 0.82 | PIK3C3 (0.60) | PIK3C3 | |
| SCHEMBL22655430 | 0.82 | PIK3C3 (0.50) | PIK3C3 | |
| SCHEMBL21612168 | 0.81 | PIK3C3 (0.65) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| US-11780858-B2 | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2023-10-10 | — | — | US | claimed |
| EP-4251163-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4169581-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2023-04-26 | — | — | EP | claimed |
| CN-111094271-B | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2023-02-28 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| EP-3672948-B1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-10-05 | — | — | EP | claimed |
| US-20220184077-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| US-20220177495-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-06-09 | — | — | US | claimed |
| WO-2022115546-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| US-11208423-B2 | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2021-12-28 | — | — | US | claimed |
| US-20200361963-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-11-19 | — | — | US | claimed |
| CN-111094271-A | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3672948-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111094271-A | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019038389-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885 |
| US-11780858-B2 | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | PDXK, PLPBP, PNPO | PIK3C3 3787/4885 |
| US-11208423-B2 | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds | PDXK, PLPBP, PNPO | PIK3C3 3838/4885 |
| US-20220177495-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3787/4885 |
| US-20200361963-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3838/4885 |
| US-20220184077-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.